Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TSSC2 is classified as a human pseudogene, meaning it shares high sequence similarity with a protein-coding gene but no longer produces a functional protein or is not known to be translated[3][4][7][12]. Located on chromosome 11p15.4, it is a transcribed, unprocessed pseudogene, meaning it may be transcribed into RNA but lacks functional protein coding capability[3][7][9][12]. TSSC2 has no known protein product, molecular function, or established biological or therapeutic role. There is no evidence to date supporting its function as a drug target, biomarker, or contributor to disease; it is not considered a druggable receptor, enzyme, transporter, or signaling molecule[1][3][4][7][12]. The abbreviation "ALG1 pseudogene" in some aliases refers to sequence similarity with asparagine-linked glycosylation 1 (ALG1), but TSSC2 is not itself an active enzyme or receptor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor suppressing subtransferable candidate 2 pseudogene (TSSC2).